Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America

Burt, R.K., Tappenden, P. orcid.org/0000-0001-6612-2332, Han, X. et al. (5 more authors) (2020) Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America. Multiple Sclerosis and Related Disorders, 45. 102404. ISSN 2211-0348

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2020 Elsevier B.V. This is an author produced version of a paper subsequently published in Multiple Sclerosis and Related Disorders. Uploaded in accordance with the publisher's self-archiving policy. Article available under the terms of the CC-BY-NC-ND licence (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Cost analysis; Outcomes comparison; Disease-modifying therapy; Hematopoietic stem cell transplantation; Multiple sclerosis
Dates:
  • Accepted: 15 July 2020
  • Published (online): 17 July 2020
  • Published: October 2020
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 23 Oct 2020 16:13
Last Modified: 17 Jul 2021 00:38
Status: Published
Publisher: Elsevier BV
Refereed: Yes
Identification Number: https://doi.org/10.1016/j.msard.2020.102404
Related URLs:

Share / Export

Statistics